The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 821-830

  Kim, Ho Sook ^a   Kim, Ga Young ^a   Yeo, Chang Woo ^a,b   Oh, Minkyung ^a   Ghim, Jong Lyul ^a   Shon, Ji Hong ^a   Kim, Eun Young ^a   Kim, Dong Hyun ^a   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

^b Dae Dong Hospital   (South Korea)

Author keywords

cilostazol; Ginkgo biloba extracts; herb drug interaction; pharmacodynamics; pharmacokinetics

Indexed keywords

3,4 DEHYDROCILOSTAZOL; 4 TRANS HYDROXYCILOSTAZOL; ADENOSINE DIPHOSPHATE; CILOSTAZOL; GINEXIN; GINKGO BILOBA EXTRACT; PLACEBO; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; PLANT EXTRACT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; KOREA; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VASCULAR HEADACHE; DRUG EFFECTS; GINKGO BILOBA; HERB DRUG INTERACTION; METABOLISM; MIDDLE AGED;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PLATELET AGGREGATION; TETRAZOLES;

EID: 84899105099     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12236     Document Type: Article

References (37)

1. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr,. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
2. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS,. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832.
3. Matsumoto M,. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6: 33-40.
4. Schror K,. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4: (Suppl. 2): S14-19.
5. Kimura Y, Tani T, Kanbe T, Watanabe K,. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144-1149.
6. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG,. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004; 76: 104-112.
7. Tamai Y, Takami H, Nakahata R, Ono F, Munakata A,. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999; 29: 269-276.
8. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ,. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008; 51: 1181-1187.
9. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ,. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
10. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE,. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000; 81: 668-678.
11. World Health Organization. WHO Monographs on Selected Medicinal Plants: Folium Ginkgo. Geneva: WHO, 1999.
12. Klepser TB, Klepser ME,. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999; 56: 125-138. quiz 39-41.
13. KFDA. Release of information: Ginexin F 80mg. Available at http://ezdrug.mfds.go.kr/kfda2 (last accessed 9 May 2013).
14. Izzo AA, Ernst E,. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163-2175.
15. Hilton MP, Zimmermann EF, Hunt WT,. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev 2013; (3) CD003852.
16. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S,. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11: 851-859.
17. Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JW,. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial. J Cardiopulm Rehabil Prev 2008; 28: 258-265.
18. Chan A, Leung H, Wu J, Chien T,. Risk of hemorrhage associated with co-prescriptions for Ginkgo biloba and antiplatelet or anticoagulant drugs. J Altern Complement Med 2011; 17: 513-517.
19. Choi K, Koh M,. Analysis of prescribing patterns of oral anti-thrombotics in outpatients-focusing on prescriptions containing multiple drugs. JKAMCP 2010; 2: 21-29.
20. Deng Y, Bi HC, Zhao LZ, Wang XD, Chen J, Ou ZM, Ding L, Xu LJ, Guan S, Chen X, Zhou SF, Huang M,. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett 2008; 2: 60-66.
21. Umegaki K, Taki Y, Endoh K, Taku K, Tanabe H, Shinozuka K, Sugiyama T,. Bilobalide in Ginkgo biloba extract is a major substance inducing hepatic CYPs. J Pharm Pharmacol 2007; 59: 871-877.
22. Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, Mizugaki M,. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 2007; 35: 1730-1732.
23. German Commission E. Liste der Monographien der E-Kommission (Phyto-Therapie). Available at http://buecher.heilpflanzen-welt.de/BGA- Kommission-E-Monographien (last accessed 11 May 2013).
24. Bramer SL, Forbes WP,. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 1999; 37: (Suppl. 2): 13-23.
25. Kim KA, Park PW, Hong SJ, Park JY,. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236-242.
26. Loscalzo J, Shafer AI,. Thrombosis and Hemorrhage, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002.
27. Bramer SL, Brisson J, Corey AE, Mallikaarjun S,. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. Clin Pharmacokinet 1999; 37: (Suppl. 2): 69-77.
28. Harnly JM, Luthria D, Chen P,. Detection of adulterated Ginkgo biloba supplements using chromatographic and spectral fingerprints. J AOAC Int 2012; 95: 1579-1587.
29. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR,. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008; 24: 591-599.
30. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS,. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-850.
31. Zou L, Harkey MR, Henderson GL,. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579-1589.
32. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S,. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46: 1290-1298.
33. Smith MLK, Zheng YP,. An open trial of nifedipine-herb interactions: nifedipine with St. John's wort, ginseng, or Gingko biloba. Clin Pharmacol Ther 2001; 69: 86.
34. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY,. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-287.
35. Ryu KH, Han HY, Lee SY, Jeon SD, Im GJ, Lee BY, Kim K, Lim KM, Chung JH,. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thromb Res 2009; 124: 328-334.
36. Braquet P,. The Ginkgolides; potent platelet activating antagonists isolated from Ginkgo biloba L; chemistry, pharmacology and clinical applications. Drugs Future 1987; 12: 643-688.
37. Pratt CM,. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87: 28D-33D.